Welcome to our dedicated page for Ultragenyx Pharm SEC filings (Ticker: RARE), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Ultragenyx Pharmaceutical Inc. filings document a rare-disease biopharmaceutical business with approved medicines, investigational genetic-disease therapies, and a Nasdaq-listed common stock capital structure. Form 8-K reports include operating results, financial guidance, FDA communications, clinical-study data, and risk language tied to drug development, regulatory review, manufacturing, funding needs, competition, and commercialization.
Proxy materials describe annual-meeting matters, board and compensation governance, equity compensation, and stockholder voting. Recent current reports also record restructuring and cost disclosures, employment-related equity plans, and material updates for programs including UX111, UX016, DTX301, DTX401, and GTX-102.
Ultragenyx Pharmaceutical Inc. (RARE) has filed a Form 144 with the U.S. Securities and Exchange Commission to notify the market of a proposed secondary sale of its equity.
- Securities: 2,405 shares of common stock
- Acquisition date & type: Restricted stock received on 05/15/2025 from the issuer
- Broker: Morgan Stanley Smith Barney LLC, 1 New York Plaza, 8th Floor, New York, NY 10004
- Planned sale date: Approximately 06/20/2025 on the NASDAQ exchange
- Estimated market value: US $89,922.95
- Total shares outstanding: 94,542,035 ⇒ proposed sale equals roughly 0.0025% of shares outstanding
- Prior 3-month sales: None reported
The filing is marked as LIVE and contains the standard representation that the seller is unaware of any undisclosed material adverse information. No additional financial data or strategic developments are included in this notice. Given the very small size of the transaction relative to Ultragenyx’s share base, the filing appears routine with limited market impact.